Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A fifty-year odyssey: prospects for a cytomegalovirus vaccine in transplant and congenital infection
Don J. Diamond, Corinna La Rosa, Flavia Chiuppesi, et al.
Expert Review of Vaccines (2018) Vol. 17, Iss. 10, pp. 889-911
Open Access | Times Cited: 50

Showing 1-25 of 50 citing articles:

Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases
Xinle Cui, Clifford M. Snapper
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 125
The Status of Vaccine Development Against the Human Cytomegalovirus
Stanley A. Plotkin, Dai Wang, Abdel Oualim, et al.
The Journal of Infectious Diseases (2019) Vol. 221, Iss. Supplement_1, pp. S113-S122
Open Access | Times Cited: 95
The nano delivery systems and applications of mRNA
Mingyuan Li, Yuan Li, Shiqin Li, et al.
European Journal of Medicinal Chemistry (2021) Vol. 227, pp. 113910-113910
Open Access | Times Cited: 92
American Society for Transplantation and Cellular Therapy Series: #3—Prevention of Cytomegalovirus Infection and Disease After Hematopoietic Cell Transplantation
Morgan Hakki, Samuel L Aitken, Lara Danziger‐Isakov, et al.
Transplantation and Cellular Therapy (2021) Vol. 27, Iss. 9, pp. 707-719
Open Access | Times Cited: 88
Progress and Challenges in the Prevention, Diagnosis, and Management of Cytomegalovirus Infection in Transplantation
Ajit P. Limaye, Tara M. Babu, Michael Boeckh
Clinical Microbiology Reviews (2020) Vol. 34, Iss. 1
Open Access | Times Cited: 84
Development of a Vaccine against Human Cytomegalovirus: Advances, Barriers, and Implications for the Clinical Practice
Sara Scarpini, Francesca Morigi, Ludovica Betti, et al.
Vaccines (2021) Vol. 9, Iss. 6, pp. 551-551
Open Access | Times Cited: 63
Poxvirus Vectored Cytomegalovirus Vaccine to Prevent Cytomegalovirus Viremia in Transplant Recipients
Ibrahim Aldoss, Corinna La Rosa, Lindsey R. Baden, et al.
Annals of Internal Medicine (2020) Vol. 172, Iss. 5, pp. 306-306
Open Access | Times Cited: 60
CMV Infection in Hematopoietic Stem Cell Transplantation: Prevention and Treatment Strategies
Niyati Jakharia, Dianna S. Howard, David J. Riedel
Current treatment options in infectious diseases/Current treatment options in infectious disease (2021) Vol. 13, Iss. 3, pp. 123-140
Open Access | Times Cited: 54
Cytomegalovirus and Inflammatory Bowel Diseases (IBD) with a Special Focus on the Link with Ulcerative Colitis (UC)
A Jentzer, Pauline Veyrard, Xavier Roblin, et al.
Microorganisms (2020) Vol. 8, Iss. 7, pp. 1078-1078
Open Access | Times Cited: 53
Bright and Early: Inhibiting Human Cytomegalovirus by Targeting Major Immediate-Early Gene Expression or Protein Function
Catherine S. Adamson, Michael Nevels
Viruses (2020) Vol. 12, Iss. 1, pp. 110-110
Open Access | Times Cited: 48
Moving Past Ganciclovir and Foscarnet: Advances in CMV Therapy
Morgan Hakki
Current Hematologic Malignancy Reports (2020) Vol. 15, Iss. 2, pp. 90-102
Open Access | Times Cited: 41
Role of Neutralizing Antibodies in CMV Infection: Implications for New Therapeutic Approaches
Virginia Martin, Estéfani García‐Ríos, Michael J. McConnell, et al.
Trends in Microbiology (2020) Vol. 28, Iss. 11, pp. 900-912
Closed Access | Times Cited: 37
Proceedings of the Conference “CMV Vaccine Development—How Close Are We?” (27–28 September 2023)
Mark R. Schleiss, Chelsea M. Crooks, Krithika P. Karthigeyan, et al.
Vaccines (2024) Vol. 12, Iss. 11, pp. 1231-1231
Open Access | Times Cited: 4
HCMV Variants Expressing ULBP2 Enhance the Function of Human NK Cells via its Receptor NKG2D
Greta Meyer, Anna Rebecca Siemes, Jenny F. Kühne, et al.
European Journal of Immunology (2025) Vol. 55, Iss. 2
Open Access
RNA-targeted proteomics identifies YBX1 as critical for efficient HCMV mRNA translation
Rebekah J. Dickmander, Erik M. Lenarcic, John D. Sears, et al.
Proceedings of the National Academy of Sciences (2025) Vol. 122, Iss. 10
Open Access
The use of peptides for deciphering the mechanism of EBV, HPV, and HCV invasion of human cells
Daniela Perdomo-Joven, Fanny Guzmán, Mauricio Urquiza
(2025)
Open Access
CMV Prevention and Treatment in Transplantation: What’s New in 2019
Anat Stern, Genovefa A. Papanicolaou
Current Infectious Disease Reports (2019) Vol. 21, Iss. 11
Open Access | Times Cited: 31
A Randomized Dose-Escalating Phase I Trial of a Replication-Deficient Lymphocytic Choriomeningitis Virus Vector-Based Vaccine Against Human Cytomegalovirus
Michael G. Schwendinger, Georges Thiry, Béatrice De Vos, et al.
The Journal of Infectious Diseases (2020) Vol. 225, Iss. 8, pp. 1399-1410
Open Access | Times Cited: 30
Immunization with Epstein–Barr Virus Core Fusion Machinery Envelope Proteins Elicit High Titers of Neutralizing Activities and Protect Humanized Mice from Lethal Dose EBV Challenge
Xinle Cui, Zhouhong Cao, Yuriko Ishikawa, et al.
Vaccines (2021) Vol. 9, Iss. 3, pp. 285-285
Open Access | Times Cited: 23
Slaying the “Troll of Transplantation”—new frontiers in cytomegalovirus management: A report from the CMV International Symposium 2023
Camille N. Kotton, Julián Torre‐Cisneros, Ibrahim Yakoub‐Agha
Transplant Infectious Disease (2023) Vol. 26, Iss. 1
Open Access | Times Cited: 8
A hidden menace? Cytomegalovirus infection is associated with reduced cortical gray matter volume in major depressive disorder
Haixia Zheng, Bart N. Ford, Maurizio Bergamino, et al.
Molecular Psychiatry (2020) Vol. 26, Iss. 8, pp. 4234-4244
Open Access | Times Cited: 23
Repertoire characterization and validation of gB-specific human IgGs directly cloned from humanized mice vaccinated with dendritic cells and protected against HCMV
Sebastian J. Theobald, Christoph Kreer, Sahamoddin Khailaie, et al.
PLoS Pathogens (2020) Vol. 16, Iss. 7, pp. e1008560-e1008560
Open Access | Times Cited: 22
Hematopoietic stem cell donor vaccination with cytomegalovirus triplex augments frequencies of functional and durable cytomegalovirus‐specific T cells in the recipient: A novel strategy to limit antiviral prophylaxis
Corinna La Rosa, Ibrahim Aldoss, Yoonsuh Park, et al.
American Journal of Hematology (2023) Vol. 98, Iss. 4, pp. 588-597
Open Access | Times Cited: 7
Development of novel vaccines against human cytomegalovirus
Xinle Cui, Clifford M. Snapper
Human Vaccines & Immunotherapeutics (2019) Vol. 15, Iss. 11, pp. 2673-2683
Open Access | Times Cited: 21
Herpesvirus Infections Potentiated by Biologics
Dora Y. Ho, Kyle T. Enriquez, Ashrit Multani
Infectious Disease Clinics of North America (2020) Vol. 34, Iss. 2, pp. 311-339
Closed Access | Times Cited: 19
Page 1 - Next Page

Scroll to top